Nyrada Inc (ASX: NYR) Share Price and News

Dr Dixon co-founded Cynata Inc in 2011, now a subsidiary of ASX-listed Cynata Therapeutics Ltd, a stem cell and regenerative medicine company. In 2014, Ian co-founded Cardio Therapeutics Pty Ltd and managed the PCSK9 cardiovascular discovery program until the company was acquired by Nyrada Inc in advance of the IPO of Nyrada in 2019. In 2018, the genetic medicines company founded by Ian listed on the ASX as Exopharm Ltd, now Entropy Neurodynamics Limited Ian was also a co-inventor of several inventions in the exosome field, including a number of granted U.S. patents.

Mr Moore is executive with leadership experience across multiple industries. He currently serves on the boards of one private and two public companies. In the life sciences sector, he is Chairman of Scientific Industries, a manufacturer of laboratory instruments, and Trialogics, a clinical trial informatics company. Until July 23, 2026, John was a shareholder and director of Cormetech. Previously, he was CEO of Acorn Energy, where he led the acquisition of CoaLogix for 11 million dollars and its later sale for 101 million dollars. He also oversaw the public listing of Comverge through Citibank and exited through a secondary offering led by Goldman Sachs at a 600 million dollars valuation prior to its sale to Constellation Energy. Earlier, in 2002, he served as Partner and CEO of Edson Moore Healthcare Ventures, managing the 148 million dollars acquisition of 16 drug delivery investments from Elan Pharmaceuticals.

Mr Bonnar was at Neuren Pharmaceuticals for eleven years. During this period, he was the Director, CMC and Regulatory Affairs and then Director, Clinical Operations where he oversaw clinical development for drugs in the areas of traumatic brain injury and neurodevelopmental disorders. Prior to that he worked in diabetes research, GMP manufacturing, and drug formulation development.

Mr Weseloh is an Executive Director of Business Development at EMD Serono, Inc, Rockland, MA, USA., where over a period of 20 years he has led more than 90 transactions for the healthcare division of its parent company Merck KGaA, Darmstadt, Germany. Completed deals across the drug development value chain were in the fields of Oncology, Rheumatology, Neurodegenerative diseases, and
Fertility. Before joining Merck KGaA, He spent 5 years as a Biotech/Pharma Equity Analyst, at Gontard & Metallbank AG, Frankfurt, and Sal. Oppenheim, Cologne/Frankfurt, as well as 3 years as a Postdoc at the Max-Planck-Institute for Experimental Medicine in Goettingen. He also served 5 years on the Supervisory Board of Cytotools AG, Freiburg, Germany.

Mr Cox is a Co-Founder and has been a Managing Partner of Population Health Partners since April 2020. Additionally, Chris is a retired Partner of Cadwalader, Wickersham and Taft LLP (New York) a position he held from January 2012. He remains a Senior Attorney of the firm. Previously the Chairman of Cadwalader Corporate Department and a member of its Management Committee, Chris advised clients corporate and financial matters, including mergers and acquisitions and restructurings, spin-offs, joint ventures, IP monetisation and other complex financing transactions. From February 2016 to March 2019, Chris was seconded to The Medicines Company, a global biopharmaceutical company, where he served as Executive Vice President and Chief Corporate Development Officer and was responsible for business development and strategy. Before January 2012, Chris was a partner at Cahill Gordon and Reindel LLP in New York. Chris also serves as the Chief Executive Officer of Symphony Capital Holdings, LLC, a private investment holding company with interests in biotechnology, network security and entertainment.

Mr Frampton currently serves as the Chief Investment Officer of the Alaska Permanent Fund Corporation (APFC), the US$94 billion wealth fund for the State of Alaska. Marcus manages the investment team at APFC and leads all investment decisions related to APFC investment portfolio within the guidelines established by APFC Board of Trustees. Before joining the APFC in 2012, Marcus held positions ranging from Investment Banking Analyst & Associate at Lehman Brothers (2002-2005), to private equity investing at PCG Capital Partners (2005-2010), and acted as an executive of a private equity-backed portfolio company at LPL Financial (2010-2012).

-

-